Tencent, Guoxin co-lead $97m Series E round in Chinese biopharma Evopoint
Tencent Investment and Guoxin Investment have jointly led a Series E funding round of 700 million yuan ($97.4 million) in Evopoint Biosciences.
Source: dealstreetasia.com
Stay updated with breaking news from Oceanpine Capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Tencent Investment and Guoxin Investment have jointly led a Series E funding round of 700 million yuan ($97.4 million) in Evopoint Biosciences.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER ...
Atleast three Indian startups—BYJU’S, NestAway, and Meesho—saw deep cuts in their valuations this week.
The top five technology industry venture financing deals in Asia-Pacific in Q3 2022 - GlobalData Deals Database
It claims to have reached unicorn status less than 18 months since its inception in April 2021